ArticleBMC medicine2025
Quantification of the IgG antibody response half-life for hybrid immunity to SARS-CoV-2.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants.Human vaccines & immunotherapeutics · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA firm understanding of SARS-CoV-2 hybrid immunity is crucial for our ongoing efforts to protect people from severe and fatal disease and assess population vulnerability to emerging novel variants. As many components of the immune response are unobserved and complex to investigate, some ambiguities and unanswered questions remain about hybrid immunity to COVID-19, such as the duration of the antibody response in individuals.
methodsTo address this, we evaluated longitudinal data that spanned up to 21 months from 52 SARS-CoV-2 naive individuals and 88 SARS-CoV-2 recovered individuals. We further separated individuals according to whether they received an mRNA or non-mRNA vaccine for their primary two-dose vaccinations. A hierarchical Bayesian framework was used to fit the parameters of mono-phasic exponential decay and bi-phasic exponential decay models to the observed data to estimate the magnitude and half-life of the spike-specific and receptor-binding domain (RBD)-specific IgG responses.
resultsResults from both our mono-phasic and bi-phasic exponential decay models estimate that the median half-life of the spike-specific and RBD-specific IgG response in individuals with hybrid immunity is almost double that of naive individuals who were only vaccinated. Recovered mRNA recipients were estimated through the mono-phasic decay model to have a median IgG response half-life of 448 days (95% CrI: [375.08, 547.54]) to spike antigen, compared to an estimated 222 days (95% CrI: [179.90, 286.62]) for naive mRNA recipients. Posterior estimates from the bi-phasic exponential decay model show that recovered individuals who received mRNA vaccinations had a median IgG response half-life of 810 days (95% CrI: [650.91, 1031.63]) to spike antigen, compared to 451 days (95% CrI: [336.81, 618.14]) for naive mRNA recipients. A similar pattern is seen in non-mRNA vaccine recipients, with IgG response half-lives differing slightly. Our results show that, across different model assumptions, individuals with hybrid immunity have an IgG response half-life that is considerably greater than that of individuals with only infection- or vaccine-induced immunity.
conclusionsOur work provides important insight into the longevity of the IgG response to SARS-CoV-2 in individuals with hybrid immunity and can guide effective immunisation approaches to maintain and improve population-level protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.